SMSatoshi Motoya

Satoshi Motoya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Satoshi Motoya has a total of 120 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Risankizumab in a Japanese Real‐World Crohn's Disease Cohort: Clinical Effectiveness in Moderate‐to‐Severely Active Disease, Endoscopic Outcomes, and Persistence

    by Yoshihiro Yokoyama, Hiroki Tanaka, Maki Miyakawa, Masanao Nasuno, Takahiro Ito, Atsuo Maemoto, Takehiko Katsurada, Katsuyoshi Ando, Aki Sakatani, Nobuhiro Ueno, et al.

    Background and Aims: Risankizumab, an interleukin‐23p19 antibody, is effective for Crohn's disease in trials; however, Japanese real‐world data remain limited. We assessed its clinical effectiveness, endoscopic outcomes, treatment persistence, and safety in a multicenter cohort. Methods: We retrospectively included patients with Crohn's disease treated with risankizumab (September 2022–February 2025) across eight centers. The CDAI‐based effectiveness analysis was restricted to patients with moderate‐to‐severely active disease at baseline (CDAI ≥ 220). Primary endpoints were corticosteroid‐free clinical remission at Weeks 12 and 52. Secondary endpoints included clinical remission and response, endoscopic response and remission, Kaplan–Meier analysis of treatment persistence, adverse events, and subgroup outcomes by prior advanced therapy and ustekinumab exposure. Segment‐based scores compared ileal and colonic outcomes at the first on‐treatment endoscopy in paired cases. Results: Among 180 patients, 51 had moderate‐to‐severely active disease at baseline and comprised the primary effectiveness population. Among evaluable patients in this population, corticosteroid‐free clinical remission rates were 31% (15/48), 52% (22/42), and 57% (16/28) at Weeks 12, 28, and 52, respectively; clinical remission rates were 40%, 55%, and 61%, respectively. Overall endoscopic response and remission rates were 58% (26/45) and 29% (13/45), respectively. Colonic endoscopic improvement outcomes favored the naïve subgroups (advanced therapy–naïve vs. advanced therapy–exposed: response 100% vs. 60%, p = 0.017; remission 80% vs. 26.7%, p = 0.009; ustekinumab‐naïve vs. ustekinumab‐exposed: response 95.2% vs. 44.4%, p = 0.005; remission 71.4% vs. 11.1%, p = 0.004). Ileal endoscopic improvement showed a similar trend but was not statistically significant. The Week 52 persistence rate was 87%; adverse events occurred in 12% of patients, with no discontinuations related to adverse events. Conclusions: Risankizumab was associated with corticosteroid‐free clinical remission among patients with moderate‐to‐severely active Crohn's disease included in the primary effectiveness analysis, together with endoscopic improvement in the paired‐endoscopy cohort. Clinical and endoscopic outcomes, as well as treatment persistence, were generally more favorable in advanced therapy‐ and ustekinumab‐naïve patients.

  • Open Access

    Data-driven subphenotyping uncovers ulcerative colitis subtype with high risk for relapse in Japan: a prospective multicenter cohort study

    by Yohei Mikami, Hajime Yamazaki, Tadakazu Hisamatsu, Masakazu Nagahori, Taku Kobayashi, Maria Yonezawa, Shinichiro Shinzaki, Toshimitsu Fujii, Masayuki Saruta, Satoshi Motoya, et al.

  • Open Access

    Data-Driven Subphenotyping Uncovers Ulcerative Colitis Subtype With High Risk for Relapse in Japan

    by Yohei Mikami, Hajime Yamazaki, Tadakazu Hisamatsu, Masakazu Nagahori, Taku Kobayashi, Maria Yonezawa, Shinichiro Shinzaki, Toshimitsu Fujii, Masayuki Saruta, Satoshi Motoya, et al.

    Background: Clinical symptoms do not necessarily align with disease activity in ulcerative colitis (UC). It remains unclear whether patient-reported outcomes (PROs), particularly quality of life (QOL) measures, can help characterize clinically meaningful subphenotypes among Japanese patients with UC in remission. This study aimed to identify and characterize UC subphenotypes using clustering analysis.Methods: We used data from a multicenter, prospective UC patient registry in Japan, called “YOu and Ulcerative colitis: Registry and Social network (YOURS)” (December 2018-June 2022). We assessed laboratory values and PRO data, including clinical symptoms and QOL data (e.g., fatigue, anxiety, disease-specific QOL), of patients with UC in remission. Discovery (N=365) and replication (N=982) datasets were independently created and subjected to clustering analysis. Data were standardized for sex (a potential confounder for various measures).Findings: PRO data correlated poorly with traditional clinical laboratory parameters. Three reproducible clusters were detected in both datasets: one cluster was characterized by lower QOL and average laboratory profiles, while the other two clusters showed preserved QOL scores either with or without distinct laboratory profiles. The cluster with lower QOL and average laboratory profiles demonstrated increased relapse rates during a 3-year follow-up in each dataset compared with the respective other two clusters.Interpretation: PRO assessments offer unique, clinically relevant data, distinct from routine biomarkers and clinical scores. Stratifying patients with UC using combined QOL and clinical laboratory parameters may help identify patients at higher risk of relapse and warrants further evaluation for its potential role in clinical decision-making.

  • Open Access

    Week 2 remission with vedolizumab as a predictor of long-term remission in patients with ulcerative colitis: a multicenter, retrospective, observational study

    by Taku Kobayashi, Tadakazu Hisamatsu, Satoshi Motoya, Toshimitsu Fujii, Reiko Kunisaki, Tomoyoshi Shibuya, Minoru Matsuura, Ken Takeuchi, Sakiko Hiraoka, Hiroshi Yasuda, et al.

    Background/Aims: Vedolizumab (VDZ), a gut-selective monoclonal antibody for ulcerative colitis (UC) treatment, has no established biomarkers or clinical features that predict long-term remission. Week 2 remission, a potential predictor of long-term remission, could inform maintenance treatment strategy. Methods: This retrospective, observational chart review included patients with UC in Japan who initiated VDZ between December 2018 and February 2020. Outcome measures included 14- and 54-week remission rates in patients with week 2 and non-week 2 remission (remission by week 14), 54-week remission rates in patients with week 14 remission and primary nonresponse, and predictive factors of week 2 and week 54 remission (logistic regression). Results: Overall, 332 patients with UC (176 biologic-naïve and 156 biologic-non-naïve) were included. Significantly more biologic-naïve than biologic-non-naïve patients achieved week 2 remission (36.9% vs. 28.2%; odds ratio [OR], 1.43; 95% confidence interval [CI], 1.05–1.94; P= 0.0224). Week 54 remission rates were significantly different between week 14 remission and primary nonresponse (both groups: P< 0.0001), and between week 2 and non-week 2 remission (all patients: OR, 2.41; 95% CI, 1.30–4.48; P= 0.0052; biologic-naïve patients: OR, 2.40; 95% CI, 1.10–5.24; P= 0.0280). Week 2 remission predictors were male sex, no anti-tumor necrosis factor alpha exposure, and normal/mild endoscopic findings. Week 54 remission was significantly associated with week 2 remission and no tacrolimus use. Conclusions: Week 2 remission with VDZ is a predictor of week 54 remission in patients with UC. Week 2 may be used as an evaluation point for UC treatment decisions. (Japanese Registry of Clinical Trials: jRCT-1080225363)


  • Open Access

    The duration of prior anti-tumor necrosis factor agents is associated with the effectiveness of vedolizumab in patients with ulcerative colitis: a real-world multicenter retrospective study

    by Taku Kobayashi, Tadakazu Hisamatsu, Satoshi Motoya, Minoru Matsuura, Toshimitsu Fujii, Reiko Kunisaki, Tomoyoshi Shibuya, Ken Takeuchi, Sakiko Hiraoka, Hiroshi Yasuda, et al.

    Background/Aims: Previous literature suggests that the response of patients with ulcerative colitis to vedolizumab may be affected by previous biologic therapy exposure. This real-world study evaluated vedolizumab treatment effectiveness in biologicnon-naïve patients. Methods: This was a multicenter, retrospective, observational chart review of records from 16 hospitals in Japan (December 1, 2018, to February 29, 2020). Included patients who had ulcerative colitis, were aged ≥ 20 years, and received at least 1 dose of vedolizumab. Outcomes included clinical remission rates from weeks 2 to 54 according to prior biologic exposure status and factors associated with clinical remission up to week 54. Results: A total of 370 eligible patients were included. Clinical remission rates were significantly higher in biologic-naïve (n=197) than in biologic-non-naïve (n=173) patients for weeks 2 to 54 of vedolizumab treatment. Higher clinical remission rates up to week 54 were significantly associated with lower disease severity (partial Mayo score ≤ 4, P= 0.001; albumin ≥ 3.0, P= 0.019) and the duration of prior anti-tumor necrosis factor α (anti-TNFα) therapy (P= 0.026). Patients with anti-TNFα therapy durations of < 3 months, 3 to < 12 months, and ≥ 12 months had clinical remission rates of 28.1%, 32.7%, and 60.0%, respectively (P= 0.001 across groups). Conclusions: The effectiveness of vedolizumab in biologic-non-naïve patients was significantly influenced by duration of prior anti-TNFα therapy. (Japanese Registry of Clinical Trials: jRCT-1080225363)


  • Open Access

    Factors affecting 1-year persistence with vedolizumab for ulcerative colitis: a multicenter, retrospective real-world study

    by Taku Kobayashi, Tadakazu Hisamatsu, Satoshi Motoya, Toshimitsu Fujii, Reiko Kunisaki, Tomoyoshi Shibuya, Minoru Matsuura, Ken Takeuchi, Sakiko Hiraoka, Hiroshi Yasuda, et al.

    Background/Aims: The objectives of this real-world study were to determine 1-year persistence with vedolizumab in patients with ulcerative colitis and to evaluate factors contributing to loss of response. Methods: In this multicenter, retrospective, observational chart review, patients with moderately to severely active ulcerative colitis who received ≥ 1 dose of vedolizumab in clinical practice at 16 tertiary hospitals in Japan (from December 2018 through February 2020) were enrolled. Results: Persistence with vedolizumab was 64.5% (n = 370); the median follow-up time was 53.2 weeks. Discontinuation due to loss of response among initial clinical remitters was reported in 12.5% (35/281) of patients. Multivariate analysis showed that concomitant use of tacrolimus (odds ratio [OR], 2.76; 95% confidence interval [CI], 1.00–7.62; P= 0.050) and shorter disease duration (OR for median duration ≥ 7.8 years vs. < 7.8 years, 0.33; 95% CI, 0.13–0.82; P= 0.017) were associated with discontinuation due to loss of response. Loss of response was not associated with prior use of anti-tumor necrosis factor alpha therapy, age at the time of treatment, disease severity, or concomitant corticosteroids or immunomodulators. Of the 25 patients with disease duration < 1 year, 32.0% discontinued due to loss of response. Conclusions: Persistence with vedolizumab was consistent with previous reports. Use of tacrolimus and shorter disease duration were the main predictors of decreased persistence.


  • Current Status of Diagnosis and Treatment of Colorectal Cancer in Asian Countries: A Questionnaire Survey

    by Hidenori Tanaka, Shiro Oka, Akiko Shiotani, Mitsushige Sugimoto, Hidekazu Suzuki, Yuji Naito, Osamu Handa, Tadakazu Hisamatsu, Shin Fukudo, Mitsuhiro Fujishiro, et al.

    Introduction: Diagnostic and therapeutic methods for colorectal cancer (CRC) have advanced; however, they may be inaccessible worldwide, and their widespread use is challenging. This questionnaire survey investigates the current status of diagnosis and treatment of early-stage CRC in Asian countries. Methods: Responses to the questionnaire were obtained from 213 doctors at different institutions in 8 countries and regions. The questionnaire consisted of 39 questions on the following four topics: noninvasive diagnosis other than endoscopy (6 questions), diagnosis by magnification and image-enhanced endoscopy (IEE) including artificial intelligence (AI) (10 questions), endoscopic submucosal dissection (ESD), proper use among other therapeutic methods (11 questions), and pathologic diagnosis and surveillance (12 questions). Results: Although 101 of 213 respondents were affiliated with academic hospitals, there were disparities among countries and regions in the dissemination of advanced technologies, such as IEE, AI, and ESD. The NICE classification is widely used for the diagnosis of colorectal tumors using IEE, while the JNET classification with magnification was used in countries such as Japan (65/70, 92.9%) and China (16/22, 72.7%). Of the 211 respondents, 208 (98.6%) assumed that en bloc resection should be achieved for carcinomas, and 180 of 212 (84.9%) believed that ESD was the most suitable in cases with a diameter larger than 2 cm. However, colorectal ESD is not widespread in countries such as Thailand, the Philippines, and Indonesia. Conclusion: The promotion of advanced technologies and education should be continual to enable more people to benefit from them.


  • Open Access

    Safety and Effectiveness of Vedolizumab in Patients with Moderate-to-Severe Ulcerative Colitis: An Interim Analysis of a Japanese Post-Marketing Surveillance Study

    by Katsuyoshi Matsuoka, Tadakazu Hisamatsu, Yohei Mikami, Takayuki Yamamoto, Satoshi Motoya, Shinichiro Shinzaki, Ryuichi Iwakiri, Kenkichi Sugiura, Kunihiko Nishimura, Mika Kajita, et al.

    Introduction This ongoing post-marketing surveillance monitors the long-term safety and effectiveness of vedolizumab in routine clinical practice in patients with moderate-to-severe ulcerative colitis (UC) in Japan. This interim analysis assessed induction-phase data, covering the initial three doses of vedolizumab. Methods Patients were enrolled via a web-based electronic data capture system from approximately 250 institutions. Incidence of adverse events and treatment responses were assessed by the physicians after the patient had received three doses of vedolizumab or when the drug was discontinued, whichever occurred first. Therapeutic response was defined as any treatment response, including remission or improvement of complete or partial Mayo score, and was assessed in the total and stratified patient populations according to prior tumor necrosis factor alpha (TNFα) inhibitor treatments and/or baseline partial Mayo score. Results The total incidence of adverse drug reactions (ADRs) was 4.10% (11/268). Common ADRs were dizziness, nausea, and arthralgia, each reported in 0.75% of patients (2/268). Serious ADRs were herpes zoster oticus and UC, each reported in 0.37% of patients (1/268). Therapeutic response was reported in 84.5% (218/258) of all patients, 85.8% (127/148) of TNFα inhibitor-naïve patients, and 82.7% (91/110) of TNFα inhibitor-experienced patients. Among patients with partial Mayo score of ≥ 4 at baseline, partial Mayo score remission in patients without or with prior TNFα inhibitor treatment was 62.5% (60/96) and 45.6% (36/79), respectively. Conclusion The results confirm a safety and effectiveness profile of vedolizumab consistent with that observed in previous trials. Clinical Trial Registration JapicCTI-194603, NCT03824561.


  • Open Access

    Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial

    by Toshifumi Hibi, Satoshi Motoya, Tadakazu Hisamatsu, Fumihito Hirai, Kenji Watanabe, Katsuyoshi Matsuoka, Masayuki Saruta, Taku Kobayashi, Brian G Feagan, Chantal Tasset, et al.

    Background/Aims: The safety and efficacy of filgotinib, a once-daily oral Janus kinase 1 preferential inhibitor, were evaluated in Japanese patients with ulcerative colitis (UC) in the phase 2b/3 SELECTION trial.Methods: SELECTION (NCT02914522) was a randomized, placebo-controlled trial comprising 2 induction studies and a maintenance study. Adults with moderately to severely active UC were randomized in induction study A (biologic-naïve) or B (biologic-experienced) to receive filgotinib 200 mg, 100 mg, or placebo once daily for 11 weeks. Patients in clinical remission or Mayo Clinic score response at week 10 entered the 47-week maintenance study. Efficacy and safety outcomes were assessed in Japanese patients enrolled in Japan.Results: Overall, 37 and 72 Japanese patients were enrolled in Japan in induction studies A and B, respectively, and 54 entered the maintenance study. Numerically higher proportions of filgotinib 200 mg-treated than placebo-treated patients achieved clinical remission in induction study A (4/15 [26.7%] vs. 0/6 [0%]) and the maintenance study (5/20 [25.0%] vs. 0/9 [0%]), but not induction study B (1/29 [3.4%] vs. 1/14 [7.1%]). Both doses were well tolerated, and no new safety signals were noted. Herpes zoster was reported in 1 filgotinib 200 mg-treated patient in each of induction study A (2.3%, 1/44) and the maintenance study (5.0%, 1/20).Conclusions: These data, alongside those of the overall SELECTION population, suggest the potential of filgotinib 200 mg as a viable treatment option for Japanese patients with UC. Owing to small patient numbers, data should be interpreted cautiously.


  • EP1316: LONG-TERM CLINICAL EFFECTIVENESS OF USTEKINUMAB IN JAPANESE PATIENTS WITH CROHN'S DISEASE: A RETROSPECTIVE COHORT STUDY

    by Takahiro Ito, Atsuo Maemoto, Takehiko Katsurada, Satoshi Motoya, Nobuhiro Ueno, Mikihiro Fujiya, Toshifumi Ashida, Daisuke Hirayama, Hiroshi Nakase